CODEL

• Research type

  Research Study

• Full title

  Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma.

• IRAS ID

  57789

• Sponsor organisation

  EORTC

• Eudract number

  2008-007295-14

• ISRCTN Number

  No number provided

• Clinicaltrials.gov Identifier

  No number provided

• Research summary

  Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (CODEL).The aim of the study is to determine whether there is a survival advantage for those patients with this rare tumour type who receive concomitant temozolomide and RT followed by adjuvant temozolomide (Stupp regimen) over that observed in patients treated with RT alone (control and current standard of care).

• REC name

  London - Brighton & Sussex Research Ethics Committee

• REC reference

  11/LO/0194

• Date of REC Opinion

  23 Sep 2011

• REC opinion

  Further Information Favourable Opinion